SEC Form 4															
FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).				EMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									OMB Number: 3235-0287 Estimated average burden hours per response: 0.5		
1. Name and Addres		2. Issuer Name and Ticker or Trading Symbol <u>PMV Pharmaceuticals, Inc.</u> [PMVP]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) C/O PMV PHAI	(First) RMACEUTICALS	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) X Officer (give title below) 01/18/2024 Chief Finan									tle Other (specify below) Sinancial Officer		
ONE RESEARCH WAY					endment, Date of	(Month/Day/Yea	6. Indiv Line)	,							
(Street) PRINCETON	NJ	08540		Form filed by More than One Reportin Person											
(City)	(State)	(Zip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											
	т	able I - No	n-Deriva	ative S	ecurities Acq	uired,	Dis	posed of, o	r Bene	ficially	Owned				
Date			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities A Disposed Of (I	Cquired D) (Instr.	(A) or 3, 4 and 5)	5. Amount of Securities Beneficially Owned Follow	F (6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
						Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
Common Stock	01/18/	/2024		A		82,220(1)	A	\$0.00	91,286		D				
		Table II -			curities Acqui Ils, warrants,						wned				

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of Transaction Code (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/\	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Employee Stock Option (right to buy)	\$ 1.8	01/18/2024		A		204,630		(2)	01/18/2034	Common Stock	204,630	\$0.00	204,630	D	

Explanation of Responses:

1. The reported shares are represented by restricted stock units, or RSUs, all of which vest on June 30, 2025.

2. Shares subject to the option vest in 48 equal monthly installments beginning on February 18, 2024.

Remarks:

/s/ Robert Ticktin, by power of 01/22/2024

** Signature of Reporting Person Date

<u>attorney</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.